Real-time disaster intelligence, alerts, and response tools.
Thursday, April 23, 2026
[ad_1] Ampersand’s AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai’s CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related […]
[ad_1] OKAYAMA, Japón, 20 de noviembre de 2024 /PRNewswire/ — Nagase Viita Co., Ltd., miembro del Grupo NAGASE con sede en Okayama (Japón), se dispone a ampliar la línea de SOLBIOTE (TM), excipientes farmacéuticos a […]
[ad_1] TORONTO, Nov. 20, 2024 /PRNewswire/ — AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company’s patented AmacaGel™ platform, demonstrating sustained anesthetic release out […]
[ad_1] SILVER SPRING, Md., Nov. 19, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a request for information […]
[ad_1] SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha–particle emitting radioisotope, actinium–225, for potential cancer treatments The two sides aim to submit an Investigational New Drug […]
